IGM Biosciences rises on FDA nod to lupus, RA treatment trials

IGM Biosciences

31/05/2023 14:54

** Shares of biotech co IGM Biosciences Inc  IGMS.O  rise 5%
to $12.16
    ** IGMS says the U.S. FDA has cleared two applications to
start studies for co's imvotamab in both severe systemic lupus
erythematosus (SLE) and severe rheumatoid arthritis 
    ** Co plans to begin patient enrolment in both studies in Q3
2023
     ** SLE is the most common type of lupus, an inflammatory
disease caused when the immune system attacks its own tissues
    ** Stock down ~28% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))